ReviewGastroenterology2012
New virologic tools for management of chronic hepatitis B and C.
Review in Gastroenterology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 132 citations in OpenAlex.
- Dried blood spot in the genotyping, quantification and storage of HCV RNA: a systematic literature review.Journal of viral hepatitis · 2015Pooled it
- HCV NS3Ag: a reliable and clinically useful predictor of antiviral outcomes in genotype 1b hepatitis C virus-infected patients.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2016Trial
- Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients.Antimicrobial agents and chemotherapy · 2014Trial
- Hepatitis C virus core antigen, an earlier and stronger predictor on sustained virological response in patients with genotype 1 HCV infection.BMC gastroenterology · 2014Trial
- Independent evolution of multi-dominant viral genome species observed in a hepatitis C virus carrier.Biochemistry and biophysics reports · 2022Article
- Evaluation of the Aptima HBV Quant Assay Compared to Abbott RealTime M2000 HBV Quant Assay and Procleix Ultrio Plus dHBV Assay in Plasma Samples.Microbiology spectrum · 2022Article
- Validation of a Genotype-Independent Hepatitis C Virus Near-Whole Genome Sequencing Assay.Viruses · 2021Article
- Whole genome deep sequencing analysis of viral quasispecies diversity and evolution in HBeAg seroconverters.JHEP reports : innovation in hepatology · 2021Article
- Review
- Performance Evaluation of the Beckman Coulter DxN VERIS Hepatitis B Virus (HBV) Assay in Comparison With the Abbott RealTime HBV Assay.Annals of laboratory medicine · 2019Article
- Evaluation of dried blood spot as an alternative sample collection method for hepatitis C virus RNA quantitation and genotyping using a commercial system.Virusdisease · 2018Article
- Approaches for simplified HCV diagnostic algorithms.Journal of the International AIDS Society · 2018Review
- A comparative study on the characterization of hepatitis B virus quasispecies by clone-based sequencing and third-generation sequencing.Emerging microbes & infections · 2017Article
- Deep sequencing analysis of quasispecies in the HBV pre-S region and its association with hepatocellular carcinoma.Journal of gastroenterology · 2017Article
- Real-time PCR assays for hepatitis B virus DNA quantification may require two different targets.Virology journal · 2017Article
- The New Aptima HBV Quant Real-Time TMA Assay Accurately Quantifies Hepatitis B Virus DNA from Genotypes A to F.Journal of clinical microbiology · 2017Article
- Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing.Scientific reports · 2017Article
- Rapid virological response assessment by Abbott RealTime hepatitis C virus assay for predicting sustained virological responses in patients with hepatitis C virus genotype 1 treated with pegylated-interferon and ribavirin.The Kaohsiung journal of medical sciences · 2016Article
- Different Variants in Reverse Transcriptase Domain Determined by Ultra-deep Sequencing in Treatment-naïve and Treated Indonesian Patients Infected with Hepatitis B Virus.The Kobe journal of medical sciences · 2016Article
- Implementation of Next-Generation Sequencing for Hepatitis B Virus Resistance Testing and Genotyping in a Clinical Microbiology Laboratory.Journal of clinical microbiology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular biology techniques are routinely used to diagnose and monitor treatment of patients with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections. These tools can detect and quantify viral genomes and analyze their sequence to determine their genotype or subtype and to identify nucleotide or amino acid substitutions associated with resistance to antiviral drugs. They include real-time target amplification methods, which have been standardized and are widely used in clinical practice to diagnose and monitor HBV and HCV infections, and next-generation sequencing techniques, which are still restricted to research laboratories. In addition, new enzyme immunoassays can quantify hepatitis B surface and hepatitis C core antigens, and point-of-care tests and alternatives to biologic tests that require whole-blood samples obtained by venipuncture have been developed. We review these new virologic methods and their clinical and research applications to HBV and HCV infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.